ClinicalTrials.gg
CompletedNCT03387202Updated Feb 7, 2018

Laparoscopic Lateral Mesh Suspension for Pelvic Organ Prolapse

An observational study in Pelvic Organ Prolapse and Pelvic Floor Prolapse, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
Female
01

Study summary

This study is aimed to share our clinical experience in an uterine-preserving laparoscopic lateral suspension of apical prolapses with mesh operation after minor modifications in technique. Transperineal ultrasonography and several questionnaires are used for objective and subjective outcomes.

Read the detailed description

Vaginal length, bladder neck mobility and pelvic floor biometry with anteroposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative 18th months if available.

Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success in the preoperative and at postoperative 18th months if available.

,

02

Conditions studied

  • Pelvic Organ Prolapse
  • Pelvic Floor Prolapse

Keywords

  • Pelvic Organ Prolapse
  • Translabial ultrasound
  • Transperineal ultrasound
  • Lateral Mesh Suspension
  • Descensus uteri
  • Laparoscopic pelvic organ prolapse repair
03

In context

Pelvic Organ Prolapse

521 studies on the registry are indexed under Pelvic Organ Prolapse; 80 are open to participants now.

This study's enrollment of 15 is below the median of 134 across 171 observational studies indexed under Pelvic Organ Prolapse.

Browse Pelvic Organ Prolapse studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 120 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Symptomatic women with pelvic organ prolapse

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years old symptomatic women with pelvic organ prolapse needing surgery.
  • Patients who are not comfortable with using or refusing pessary
  • Refusing sacrocolpopexy due to its serious surgical risk

Exclusion criteria

Exclusion Criteria:

  • Patients who prefer sacrocolpopexy
  • Any cue for gynecologic oncological condition
  • Patients who approves Le Fort colpocleisis among who does not have any sexual intercourse
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • pelvic organ prolapse

    Participants received "Laparoscopic lateral suspension with mesh" as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success.

    Procedure: Laparoscopic lateral suspension with mesh · Diagnostic Test: Transperineal ultrasound

Interventions

  • ProcedureLaparoscopic lateral suspension with mesh

    V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level

  • Diagnostic testTransperineal ultrasound

    Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.

    Also known as: Translabial ultrasound

06

What researchers measure

Primary outcomes

  1. Change from baseline POP-Q measurements (mm) at 18th month.

    Prolapse degree; Point Ba/C/Bp

    Time frame: 18 months

Secondary outcomes

  1. Subjective Success - Change from baseline Female Sexual Function Index (FSFI) to measure sexual dysfunction at 18th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. The FSFI is a multiple-trait scoring, self-report document used to assess female SF during the previous 4 weeks. It consists of 19 items that encompass six separate domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The maximum score is 36 points and the minimum score is 2 points. After completion of the questionnaire, the total SF score was calculated as follows: no sexual dysfunction (SD) (≥ 30 points) , mild SD (between \<29 and \> 23 points), and severe SD (≤ 22 points).

    Time frame: 18 months

  2. Subjective Success - Change from baseline Michigan Incontinence Severity Index (M-ISI) to measure urinary incontinence at 18th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. It has ten items, consisting of a total M-ISI domain (the sum of items 1-8) and a distinct Bother domain (the sum of items 9 and 10). The total M-ISI score consists of three subdomains (items 1-3 for stress urinary incontinence \[SUI\], items 4-6 for UUI, and items 7 and 8 for PU). The responses for each item range from 0 to 4 on a Likert-type scale, with higher values representing greater symptoms and greater bother. The total M-ISI domain ranges from 0 to 32, the Bother domain ranges from 0 to 8, the SUI and UUI subdomains range from 0 to 12, and the PU subdomain ranges from 0 to 8. Total domain and subdomain scores are obtained by simply adding the respective answers. The minimally important difference has been determined for the following domains/subdomains: total M-ISI (4 points), SUI (2 points), UUI (2 points), and PU (1 point).

    Time frame: 18 months

  3. Subjective Success - Change from baseline Prolapse Quality of Life questionnaire (PQoL) to measure quality of life according to pelvic organ prolapse at 18th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. he questionnaire included 20 questions grouped in sections (domains) related to a particular aspect of quality of life. A total of nine domains covering general health, prolapse impact, role limitations, physical and social limitations, personal relationships, emotional problems, sleep/energy disturbance as well as severity symptoms measurements were defined. Questions regarding bladder, bowel and sexual function were also separately included and validated for reproducibility and internal consistency. Responses ranged from 'none/not at all', through 'slightly/a little' and 'moderately' to 'a lot' to produce a four-point scoring system for each item. Scores in each domain ranged between 0 and 100 with a high total score indicating a greater impairment of quality of life.

    Time frame: 18 months

  4. Subjective Success - Change from baseline Pelvic Organ Prolapse Symptom Score (POP-SS) to measure quality of life according to pelvic organ prolapse at 18th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. Total range scores: 28 (min:0, max:28). Higher values represent a worse outcome.

    Time frame: 18 months

  5. Subjective Success - Change from baseline Visual Analog Score (VAS) for pain at 18th month.

    Participant describes the pain related to the mesh. The respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain with a format of a horizontal bar.

    Time frame: 18 months

  6. Change from baseline Pelvic Hiatus measurements (mm) at 18th month.

    Anteroposterior hiatal length (mm)

    Time frame: 18 months

  7. Change from baseline Pelvic biometry measurements at 18th month.

    Prolapse degree over symphysis pubis (mm) Anterior compartment over 10, Posterior compartment over 15 mm are clinically relevant

    Time frame: 18 months

  8. Change from baseline bladder neck mobility measurements at 18th month.

    Urethral rotation (degree) between rest and valsalva maneuver states

    Time frame: 18 months

  9. Failure (%)

    Failure is defined by any recurrence of prolapse, mesh erosion and need for additional surgery

    Time frame: 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol

Supporting information: Study protocol

Time frame: Immediately, until the publishing

Access criteria: Study protocol can be sent upon request murat.yassa@gmail.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jan 2018, 14 months.

Of 55 non-industry observational studies under Pelvic Organ Prolapse, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 14 months is below that.

Counting every sponsor, half of 61 studies reached it within 31 months; a quarter within 16 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2017
First posted
Jan 2, 2018
StartActual
Nov 1, 2016
Primary completionActual
Jan 12, 2018
CompletionActual
Feb 5, 2018
Last update
Feb 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03387202
Responsible party
MURAT YASSA (Principal Investigator, Fatih Sultan Mehmet Training and Research Hospital) — Principal investigator
First posted
Jan 2, 2018
Start date
Nov 1, 2016
Primary completion
Jan 12, 2018
Completion
Feb 5, 2018
Last update
Feb 7, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion